Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Teva Pharmaceutical Industries Ltd and Takeda Announce Agreement for Glatiramer Acetate for Multiple Sclerosis Treatment in Japan


Wednesday, 4 Dec 2013 02:27am EST 

Teva Pharmaceutical Industries Ltd:Says the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva's glatiramer acetate ( active ingredient) formulation for the treatment of multiple sclerosis, in Japan.Says Teva and Takeda are currently working on further agreements in connection with the implementation of this license.Says developed by Teva, glatiramer acetate for injection is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with multiple scleros.Says under the terms of the agreement, Teva will grant Takeda commercialization rights in Japan, and Takeda will submit a New Drug Application for registration of glatiramer acetate in Japan.Says Teva and Takeda will work under close cooperation so that both parties can provide a new treatment option to patients with multiple sclerosis in Japan as early as possible, where the current available therapies are still limited. 

Company Quote

5787.0
 --
27 Jan 2015